{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:12:26Z","timestamp":1794492746344,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00016"],"award-info":[{"award-number":["75N93021C00016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00016"],"award-info":[{"award-number":["75N93021C00016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69721-5","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:38:56Z","timestamp":1771508336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1757-4532","authenticated-orcid":false,"given":"Konstantin","family":"Andreev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-2112","authenticated-orcid":false,"given":"Jeremy C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3253-6961","authenticated-orcid":false,"given":"Ahmed","family":"Kandeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-0545","authenticated-orcid":false,"given":"Peter","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-7132","authenticated-orcid":false,"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-5682","authenticated-orcid":false,"given":"Elena A.","family":"Govorkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"69721_CR1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","volume":"378","author":"H Nair","year":"2011","unstructured":"Nair, H. et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 378, 1917\u20131930 (2011).","journal-title":"Lancet"},{"key":"69721_CR2","doi-asserted-by":"crossref","unstructured":"Swayne, D. E. et al. Strategic challenges in the global control of high pathogenicity avian influenza. Rev. Sci. Tech. Special Edition, 89\u2013102 (2024).","DOI":"10.20506\/rst.SE.3563"},{"key":"69721_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2414610","volume":"392","author":"S Garg","year":"2025","unstructured":"Garg, S. et al. Highly pathogenic avian influenza A(H5N1) virus infections in humans. N. Engl. J. Med. 392, 843\u2013854 (2025).","journal-title":"N. Engl. J. Med."},{"key":"69721_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/viro.1999.9820","volume":"261","author":"X Xu","year":"1999","unstructured":"Xu, X., Subbarao, Cox, N. J. & Guo, Y. Genetic characterization of the pathogenic influenza A\/Goose\/Guangdong\/1\/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261, 15\u201319 (1999).","journal-title":"Virology"},{"key":"69721_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57338-z","volume":"16","author":"C Pardo-Roa","year":"2025","unstructured":"Pardo-Roa, C. et al. Cross-species and mammal-to-mammal transmission of clade 2.3.4.4b highly pathogenic avian influenza A\/H5N1 with PB2 adaptations. Nat. Commun. 16, 2232 (2025).","journal-title":"Nat. Commun."},{"key":"69721_CR6","unstructured":"Rolfes, M. A. et al. Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025. Nat. Med. 31, 3889\u20133898 (2025)."},{"key":"69721_CR7","doi-asserted-by":"crossref","unstructured":"Bruno, A. et al. First case of human infection with highly pathogenic H5 avian Influenza A virus in South America: a new zoonotic pandemic threat for 2023? J. Travel Med. 30, taad032 (2023).","DOI":"10.1093\/jtm\/taad032"},{"key":"69721_CR8","doi-asserted-by":"crossref","unstructured":"Castillo, A. et al. The first case of human infection with H5N1 avian Influenza A virus in Chile. J. Travel Med. 30, taad083 (2023).","DOI":"10.1093\/jtm\/taad083"},{"key":"69721_CR9","doi-asserted-by":"crossref","unstructured":"Kandeil, A. et al. Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America. Nat. Commun. 14, 3082 (2023).","DOI":"10.1038\/s41467-023-38415-7"},{"key":"69721_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12985-025-02760-4","volume":"22","author":"JH Song","year":"2025","unstructured":"Song, J. H. et al. Intranasally administered whole virion inactivated vaccine against clade 2.3.4.4b H5N1 influenza virus with optimized antigen and increased cross-protection. Virol. J. 22, 131 (2025).","journal-title":"Virol. J."},{"key":"69721_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61964-y","volume":"16","author":"N Patel","year":"2025","unstructured":"Patel, N. et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M((R)) nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat. Commun. 16, 6625 (2025).","journal-title":"Nat. Commun."},{"key":"69721_CR12","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2213-2600(25)00052-9","volume":"13","author":"J Taaffe","year":"2025","unstructured":"Taaffe, J. et al. An overview of influenza H5 vaccines. Lancet Respir. Med. 13, e20\u2013e21 (2025).","journal-title":"Lancet Respir. Med."},{"key":"69721_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61757-3","volume":"16","author":"TP Fabrizio","year":"2025","unstructured":"Fabrizio, T. P. et al. Genotype B3.13 influenza A(H5N1) viruses isolated from dairy cattle demonstrate high virulence in laboratory models, but retain avian virus-like properties. Nat. Commun. 16, 6771 (2025).","journal-title":"Nat. Commun."},{"key":"69721_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41564-025-01961-5","volume":"10","author":"JC Jones","year":"2025","unstructured":"Jones, J. C. et al. Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow\u2019s milk. Nat. Microbiol. 10, 836\u2013840 (2025).","journal-title":"Nat. Microbiol."},{"key":"69721_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105959","volume":"229","author":"K Andreev","year":"2024","unstructured":"Andreev, K. et al. Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors. Antivir. Res. 229, 105959 (2024).","journal-title":"Antivir. Res."},{"key":"69721_CR16","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/infdis\/jiad418","volume":"229","author":"K Andreev","year":"2024","unstructured":"Andreev, K. et al. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) Viruses Circulating Globally in 2022-2023. J. Infect. Dis. 229, 1830\u20131835 (2024).","journal-title":"J. Infect. Dis."},{"key":"69721_CR17","doi-asserted-by":"publisher","first-page":"e2514508","DOI":"10.1001\/jamanetworkopen.2025.14508","volume":"8","author":"AD Bai","year":"2025","unstructured":"Bai, A. D., Srivastava, S., Al Baluki, T., Razak, F. & Verma, A. A. Oseltamivir treatment vs supportive care for seasonal influenza requiring hospitalization. JAMA Netw. Open 8, e2514508\u2013e2514508 (2025).","journal-title":"JAMA Netw. Open"},{"key":"69721_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden, F. G. et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379, 913\u2013923 (2018).","journal-title":"N. Engl. J. Med."},{"key":"69721_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 93, 449\u2013463 (2017).","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"69721_CR20","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki, K. & Daikoku, T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 209, 107512 (2020).","journal-title":"Pharmacol. Ther."},{"key":"69721_CR21","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","volume":"366","author":"RA Bright","year":"2005","unstructured":"Bright, R. A. et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366, 1175\u20131181 (2005).","journal-title":"Lancet"},{"key":"69721_CR22","doi-asserted-by":"publisher","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","volume":"10","author":"G Dong","year":"2015","unstructured":"Dong, G. et al. Adamantane-Resistant Influenza A Viruses in the World (1902\u20132013): frequency and Distribution of M2 Gene Mutations. PLOS ONE 10, e0119115 (2015).","journal-title":"PLOS ONE"},{"key":"69721_CR23","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1128\/AAC.01739-09","volume":"54","author":"K Sleeman","year":"2010","unstructured":"Sleeman, K. et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54, 2517\u20132524 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69721_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","volume":"24","author":"LV Gubareva","year":"2019","unstructured":"Gubareva, L. V. et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons. Eurosurveillance 24, 13\u201317 (2019).","journal-title":"Eurosurveillance"},{"key":"69721_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1128\/jvi.67.4.1761-1764.1993","volume":"67","author":"EK Subbarao","year":"1993","unstructured":"Subbarao, E. K., London, W. & Murphy, B. R. A single amino-acid in the Pb2-gene of influenza-A virus is a determinant of host range. J. Virol. 67, 1761\u20131764 (1993).","journal-title":"J. Virol."},{"key":"69721_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0073-6","volume":"7","author":"S Liu","year":"2018","unstructured":"Liu, S. et al. Substitution of D701N in the PB2 protein could enhance the viral replication and pathogenicity of Eurasian avian-like H1N1 swine influenza viruses. Emerg. Microbes Infect. 7, 75 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"69721_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fmicb.2017.00575","volume":"8","author":"A Nieto","year":"2017","unstructured":"Nieto, A. et al. Identification of Rare PB2-D701N mutation from a patient with severe influenza: contribution of the PB2-D701N mutation to the pathogenicity of human influenza. Front. Microbiol. 8, 575 (2017).","journal-title":"Front. Microbiol."},{"key":"69721_CR28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ejcb.2015.05.012","volume":"94","author":"H Sediri","year":"2015","unstructured":"Sediri, H., Schwalm, F., Gabriel, G. & Klenk, H.-D. Adaptive mutation PB2 D701N promotes nuclear import of influenza vRNPs in mammalian cells. Eur. J. Cell Biol. 94, 368\u2013374 (2015).","journal-title":"Eur. J. Cell Biol."},{"key":"69721_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep14170","volume":"5","author":"W Zhu","year":"2015","unstructured":"Zhu, W. et al. Dual E627K and D701N mutations in the PB2 protein of A(H7N9) influenza virus increased its virulence in mammalian models. Sci. Rep. 5, 14170 (2015).","journal-title":"Sci. Rep."},{"key":"69721_CR30","doi-asserted-by":"publisher","first-page":"12062","DOI":"10.1128\/JVI.00684-11","volume":"85","author":"A Rodriguez","year":"2011","unstructured":"Rodriguez, A., P\u00e9rez-Gonz\u00e1lez, A. & Nieto, A. Cellular human CLE\/C14orf166 protein interacts with influenza virus polymerase and is required for viral replication. J. Virol. 85, 12062\u201312066 (2011).","journal-title":"J. Virol."},{"key":"69721_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60407-y","volume":"16","author":"T Tipih","year":"2025","unstructured":"Tipih, T. et al. Highly pathogenic avian influenza H5N1 clade 2.3.4.4b genotype B3.13 is highly virulent for mice, rapidly causing acute pulmonary and neurologic disease. Nat. Commun. 16, 5738 (2025).","journal-title":"Nat. Commun."},{"key":"69721_CR32","doi-asserted-by":"crossref","unstructured":"Aoki FY. 44 - Antiviral Drugs for Influenza and Other Respiratory Virus Infections. In: Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases (Eighth Edition) (eds Bennett, J. E., Dolin, R. & Blaser, M. J.) (W.B. Saunders, 2015).","DOI":"10.1016\/B978-1-4557-4801-3.00044-8"},{"key":"69721_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00003088-198814010-00003","volume":"14","author":"FY Aoki","year":"1988","unstructured":"Aoki, F. Y. & Sitar, D. S. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14, 35\u201351 (1988).","journal-title":"Clin. Pharmacokinet."},{"key":"69721_CR34","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.02440-12","volume":"57","author":"CR Rayner","year":"2013","unstructured":"Rayner, C. R. et al. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob. Agents Chemother. 57, 3478\u20133487 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69721_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jac\/dkaa393","volume":"76","author":"Y Ando","year":"2021","unstructured":"Ando, Y. et al. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection. J. Antimicrob. Chemother. 76, 189\u2013198 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"69721_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103204","volume":"63","author":"MG Ison","year":"2021","unstructured":"Ison, M. G. & Scheetz, M. H. Understanding the pharmacokinetics of Favipiravir: implications for treatment of influenza and COVID-19. EBioMedicine 63, 103204 (2021).","journal-title":"EBioMedicine"},{"key":"69721_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra0707279","volume":"358","author":"AN Abdel-Ghafar","year":"2008","unstructured":"Abdel-Ghafar, A. N. et al. Update on Avian Influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358, 261\u2013273 (2008).","journal-title":"N. Engl. J. Med."},{"key":"69721_CR38","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14656566.2024.2370895","volume":"25","author":"M Bassetti","year":"2024","unstructured":"Bassetti, M., Sepulcri, C., Giacobbe, D. R. & Fusco, L. Treating influenza with neuraminidase inhibitors: an update of the literature. Expert Opin. Pharmacother. 25, 1163\u20131174 (2024).","journal-title":"Expert Opin. Pharmacother."},{"key":"69721_CR39","unstructured":"In: Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program (National Academies Press, 2008)."},{"key":"69721_CR40","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/jac\/dki018","volume":"55","author":"P Ward","year":"2005","unstructured":"Ward, P., Small, I., Smith, J., Suter, P. & Dutkowski, R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55, i5\u2013i21 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"69721_CR41","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","volume":"71","author":"A Loregian","year":"2014","unstructured":"Loregian, A., Mercorelli, B., Nannetti, G., Compagnin, C. & Palu, G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol. Life Sci. 71, 3659\u20133683 (2014).","journal-title":"Cell Mol. Life Sci."},{"key":"69721_CR42","doi-asserted-by":"crossref","unstructured":"Gu, C. Y. et al. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature 636, 711\u2013718 (2024).","DOI":"10.1038\/s41586-024-08254-7"},{"key":"69721_CR43","doi-asserted-by":"crossref","unstructured":"Kiso, M., Uraki, R., Yamayoshi, S. & Kawaoka, Y. Efficacy of baloxavir marboxil against bovine H5N1 virus in mice. Nat Commun 16, 5356 (2025).","DOI":"10.1038\/s41467-025-60791-5"},{"key":"69721_CR44","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1128\/AAC.01667-08","volume":"53","author":"EA Govorkova","year":"2009","unstructured":"Govorkova, E. A. et al. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob. Agents Chemother. 53, 3088\u20133096 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69721_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1473-3099(06)70684-3","volume":"7","author":"HJ Sch\u00fcnemann","year":"2007","unstructured":"Sch\u00fcnemann, H. J. et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 7, 21\u201331 (2007).","journal-title":"Lancet Infect. Dis."},{"key":"69721_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.medj.2023.11.001","volume":"5","author":"W Guan","year":"2024","unstructured":"Guan, W. et al. Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus. Med 5, 32\u201341.e35 (2024).","journal-title":"Med"},{"key":"69721_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1084\/jem.20051938","volume":"203","author":"R Salomon","year":"2006","unstructured":"Salomon, R. et al. The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A\/Vietnam\/1203\/04. J. Exp. Med. 203, 689\u2013697 (2006).","journal-title":"J. Exp. Med."},{"key":"69721_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bsheal.2020.04.004","volume":"2","author":"Q Fang","year":"2020","unstructured":"Fang, Q. & Wang, D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosaf. Health 2, 64\u201370 (2020).","journal-title":"Biosaf. Health"},{"key":"69721_CR49","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","volume":"49","author":"Y Furuta","year":"2005","unstructured":"Furuta, Y. et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49, 981\u2013986 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69721_CR50","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3201\/eid3104.241820","volume":"31","author":"PNQ Pascua","year":"2025","unstructured":"Pascua, P. N. Q. et al. Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023-2024. Emerg. Infect. Dis. 31, 751\u2013760 (2025).","journal-title":"Emerg. Infect. Dis."},{"key":"69721_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0022-3565(25)24483-4","volume":"244","author":"R Spector","year":"1988","unstructured":"Spector, R. Transport of amantadine and rimantadine through the blood-brain barrier.  J. Pharmacol. Exp. Ther. 244, 516\u2013519 (1988).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"69721_CR52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/135965350701200302","volume":"12","author":"NA Ilyushina","year":"2007","unstructured":"Ilyushina, N. A., Hoffmann, E., Salomon, R., Webster, R. G. & Govorkova, E. A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12, 363\u2013370 (2007).","journal-title":"Antivir. Ther."},{"key":"69721_CR53","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1128\/AAC.01012-08","volume":"53","author":"DF Smee","year":"2009","unstructured":"Smee, D. F., Hurst, B. L., Wong, M. H., Bailey, K. W. & Morrey, J. D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53, 2120\u20132128 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69721_CR54","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.tins.2023.08.002","volume":"46","author":"L Bauer","year":"2023","unstructured":"Bauer, L., Benavides, F. F. W., Veldhuis Kroeze, E. J. B., de Wit, E. & van Riel, D. The neuropathogenesis of highly pathogenic avian influenza H5Nx viruses in mammalian species including humans. Trends Neurosci. 46, 953\u2013970 (2023).","journal-title":"Trends Neurosci."},{"key":"69721_CR55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.virol.2010.01.036","volume":"401","author":"BW Leung","year":"2010","unstructured":"Leung, B. W., Chen, H. & Brownlee, G. G. Correlation between polymerase activity and pathogenicity in two duck H5N1 influenza viruses suggests that the polymerase contributes to pathogenicity. Virology 401, 96\u2013106 (2010).","journal-title":"Virology"},{"key":"69721_CR56","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison, M. G. et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.  Lancet Infect. Dis. 20, 1204\u20131214 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"69721_CR57","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jmii.2021.04.002","volume":"54","author":"YC Kuo","year":"2021","unstructured":"Kuo, Y. C., Lai, C. C., Wang, Y. H., Chen, C. H. & Wang, C. Y. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials. J. Microbiol. Immunol. Infect. 54, 865\u2013875 (2021).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"69721_CR58","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/jac\/dkaa252","volume":"75","author":"S Shah","year":"2020","unstructured":"Shah, S. et al. Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza A. J. Timicrob. Chemother. 75, 3015\u20133022 (2020).","journal-title":"J. Timicrob. Chemother."},{"key":"69721_CR59","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40121-025-01131-4","volume":"14","author":"N Ishiguro","year":"2025","unstructured":"Ishiguro, N. et al. Clinical and virologic outcomes of baloxavir compared with oseltamivir in pediatric patients with influenza in Japan. Infect. Dis. Ther. 14, 833\u2013846 (2025).","journal-title":"Infect. Dis. Ther."},{"key":"69721_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/dkg007","volume":"51","author":"FY Aoki","year":"2003","unstructured":"Aoki, F. Y. et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51, 123\u2013129 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"69721_CR61","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","volume":"283","author":"JJ Treanor","year":"2000","unstructured":"Treanor, J. J. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283, 1016\u20131024 (2000).","journal-title":"JAMA"},{"key":"69721_CR62","doi-asserted-by":"crossref","unstructured":"Leang, S. K. & Hurt, A. C. Fluorescence-based neuraminidase inhibition assay to assess the susceptibility of influenza viruses to the neuraminidase inhibitor class of antivirals. J. Vis. Exp. 122, 55570 (2017).","DOI":"10.3791\/55570-v"},{"key":"69721_CR63","doi-asserted-by":"crossref","unstructured":"Patel, M. C. et al. An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance. Antivir. Res. 208, 105457 (2022).","DOI":"10.1016\/j.antiviral.2022.105457"},{"key":"69721_CR64","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric-estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"69721_CR65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"69721_CR66","unstructured":"Hall, T. A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. Nucleic Acids Symp. Ser.\u00a041, 95\u201398 (1999)."},{"key":"69721_CR67","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","volume":"115","author":"DH Goldhill","year":"2018","unstructured":"Goldhill, D. H. et al. The mechanism of resistance to favipiravir in influenza. Proc. Natl. Acad. Sci. USA 115, 11613\u201311618 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69721-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:02:04Z","timestamp":1774627324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69721-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69721"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69721-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7768971\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2937"}}